Upstream Bio, Inc. (UPB)
7.18
+0.57
(+8.62%)
USD |
NASDAQ |
Aug 25, 16:00
7.18
0.00 (0.00%)
Pre-Market: 19:59
Upstream Bio Enterprise Value : 132.90M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 132.90M |
| August 24, 2026 | 101.68M |
| August 21, 2026 | 121.40M |
| August 20, 2026 | 114.83M |
| August 19, 2026 | 151.25M |
| August 18, 2026 | 114.83M |
| August 17, 2026 | 130.71M |
| August 14, 2026 | 126.88M |
| August 13, 2026 | 118.11M |
| August 12, 2026 | 118.11M |
| August 11, 2026 | 127.97M |
| August 10, 2026 | 147.14M |
| August 07, 2026 | 136.74M |
| August 06, 2026 | 115.92M |
| August 05, 2026 | 108.80M |
| August 04, 2026 | 111.54M |
| August 03, 2026 | 91.28M |
| July 31, 2026 | 85.25M |
| July 30, 2026 | 99.49M |
| July 29, 2026 | 90.73M |
| July 28, 2026 | 90.18M |
| July 27, 2026 | 90.18M |
| July 24, 2026 | 90.73M |
| July 23, 2026 | 90.18M |
| July 22, 2026 | 100.59M |
| Date | Value |
|---|---|
| July 21, 2026 | 121.95M |
| July 20, 2026 | 121.95M |
| July 17, 2026 | 123.59M |
| July 16, 2026 | 135.64M |
| July 15, 2026 | 137.83M |
| July 14, 2026 | 130.71M |
| July 13, 2026 | 138.38M |
| July 10, 2026 | 152.07M |
| July 09, 2026 | 167.41M |
| July 08, 2026 | 176.72M |
| July 07, 2026 | 170.15M |
| July 06, 2026 | 144.95M |
| July 02, 2026 | 150.98M |
| July 01, 2026 | 138.38M |
| June 30, 2026 | 118.66M |
| June 29, 2026 | 83.67M |
| June 26, 2026 | 73.87M |
| June 25, 2026 | 52.65M |
| June 24, 2026 | 52.10M |
| June 23, 2026 | 50.47M |
| June 22, 2026 | 49.38M |
| June 18, 2026 | 46.66M |
| June 17, 2026 | 41.22M |
| June 16, 2026 | 28.70M |
| June 15, 2026 | 38.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sutro Biopharma, Inc. | 440.89M |
| Compass Therapeutics, Inc. | 285.38M |
| ACADIA Pharmaceuticals, Inc. | 4.379B |
| Alnylam Pharmaceuticals, Inc. | 31.79B |
| Anika Therapeutics, Inc. | 273.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.70M |
| Revenue (Quarterly) | 0.773M |
| Total Expenses (Quarterly) | 40.48M |
| EPS Diluted (Quarterly) | -0.7276 |
| Gross Profit Margin (Quarterly) | 93.53% |
| Profit Margin (Quarterly) | -5.14K% |
| Earnings Yield | -40.20% |
| Normalized Earnings Yield | -40.16 |